Investment Reports
Get to know the rationale behind great ideas for you to make sound long term investment decisions.
-
Result Update:Britannia Inds.
Result Update:Britannia Inds.09 Nov 2026
Stocks covered (1)
With an upside of 16% from the CMP, we maintain our BUY rating. -
Result Update:Va Tech Wabag
Result Update:Va Tech Wabag09 Nov 2026
-
Result Update:Sansera Enginee.
Result Update:Sansera Enginee.09 Nov 2026
Stocks covered (1)
We maintain our BUY rating on the stock, supported by strong Q2FY27 performance, with revenue, EBITDA and PAT growing 32%, 48% and 52% YoY, respectively. -
Result Update:Prestige Estates
Result Update:Prestige Estates09 Nov 2026
Stocks covered (1)
We raise our estimates for presales in this quarter to Rs 40,000 Cr from Rs 36,000 Cr and maintain our BUY recommendation on the stock. We continue to value the company using a DCF-based valuation to arrive at a new TP of Rs 1,950/share, implying a 21% upside from the CMP. -
Result Update:SignatureGlobal
Result Update:SignatureGlobal09 Nov 2026
Stocks covered (1)
We now value the company using an EV/EBITDA framework and have moderated the bookings growth assumption for FY28E to reflect a maturing Gurugram market. Despite these revisions, we maintain our BUY rating. -
Result Update:Arvind SmartSp.
Result Update:Arvind SmartSp.09 Nov 2026
Stocks covered (1)
With a 23% upside from the CMP, we maintain our long-term BUY rating on the stock. -
Result Update:LG Electronics
Result Update:LG Electronics09 Nov 2026
Stocks covered (1)
We value LGEIL at 47x FY28E EPS. We maintain our BUY rating on the stock, and revise our target price upwards to Rs 1,965/share, implying an upside of 11% from the CMP. -
Result Update:Tata Steel
Result Update:Tata Steel09 Nov 2026
-
Result Update:Fortis Health.
Result Update:Fortis Health.09 Nov 2026
Stocks covered (1)
Maintain BUY; upside potential remains capped in the near term as FY27 EBITDA margins settle near ~22% (vs. our earlier 23% base case). While hospital execution, Agilus turnaround (26.2% EBITDA margin), and bed ramp-ups (Manesar, Suguna) remain firmly on track.